Related Experiment Video

Updated: Dec 25, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.7K

Role of BET Inhibitors in Triple Negative Breast Cancers

Durga Khandekar1, Venkataswarup Tiriveedhi1,2

  • 1Department of Biological Sciences, Tennessee State University, 3500 John A Merritt Blvd, Nashville, TN 37209, USA.

Cancers
|March 29, 2020
PubMed

Insights

Bromodomain and extraterminal domain (BET) inhibitors show promise in cancer therapy, but monotherapy results are inconclusive. Combinatorial strategies are being explored to enhance efficacy, particularly in triple-negative breast cancer.

Area of Science:

  • Molecular biology
  • Oncology
  • Pharmacology

Background:

  • Bromodomain and extraterminal domain (BET) proteins regulate gene expression, influencing cell proliferation and cancer development.
  • Preclinical data support BET inhibitors in various cancer models, leading to numerous ongoing clinical trials.

Purpose of the Study:

  • To review the molecular mechanisms of BET inhibitors in cancer.
  • To summarize preliminary clinical outcomes of BET inhibitors.
  • To focus on their application in triple-negative breast cancer.

Main Methods:

  • Literature review of preclinical and clinical studies on BET inhibitors.
  • Analysis of gene expression regulation by BET proteins.
  • Evaluation of clinical trial data for BET inhibitor efficacy.

Main Results:

  • BET inhibitors modulate transcriptional machinery involved in carcinogenesis.
  • Current clinical trials show limited efficacy for BET inhibitors as monotherapy.
  • The combinatorial potential of BET inhibitors with other cancer treatments requires further investigation.

Conclusions:

  • BET inhibitors are key regulators of gene expression with potential in cancer therapy.
  • Monotherapy with BET inhibitors has not yet proven effective in clinical settings.
  • Further research is needed to optimize combinatorial approaches involving BET inhibitors, especially for triple-negative breast cancer.
Keywords:
breast cancerbromodomainscancer biologydrug discoveryimmunotherapy

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
379
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K